Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Combined With Eribulin for Recurrent HER2-Negative Breast Cancer
NCT05263882Phase 2Unknown
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of eribulin and gemcitabine in breast cancer, sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
eribulingemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05263882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263882.